CareDx’s AlloSeq cfDNA and QTYPE Solutions Featured at EFI 2019
BRISBANE, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that new data from studies on AlloSeq cfDNA and QTYPE will be featured in multiple podium and poster presentations at the annual European Immunogenetics and Histocompatibility Conference (EFI) in Lisbon, Portugal on May 8-11, 2019.
CareDx continues its dedication to innovation in transplantation with two oral presentations and three posters at EFI, and highlights its leadership with the only presentations on cfDNA in transplantation.
Additionally, CareDx will host a lunch symposium titled “Innovation in Transplant Diagnostics: Pushing the Boundaries of Transplant Solutions” on Thursday, May 9, 2019, 12:15 p.m. – 1:00 p.m. at the Centro Cultural de Belém. The symposium features two leaders in the transplant field:
-- Gottfried Fischer, MD, Medical University of Vienna, presenting data on AlloSeq cfDNA -- Milena Vrana, Head of HLA department, Institute of Hematology and Blood Transfusion, Prague, Czech Republic presenting data on QTYPE
Donor-Derived Cell-Free DNA Correlates With Rejection in Kidney Allografts
TARGETED Gene Sequencing Following Enrichment using Capture Probes: The Next Generation of Genetic Matching in Transplantation
Donor-Derived Cell-Free DNA Levels Are Independent Of Degree Of Mismatch and Donor Type
AlloSeq CfDNA, A Donor-Derived Cell-Free DNA Measurement Solution For On-Site Monitoring of Solid Organ Transplants
QTYPE, the Fastest Method for HLA Genotyping by Real-Time PCR
“Transplant is global and CareDx is committed to providing best in class solutions for transplant patients around the world,” said Peter Maag, Chief Executive Officer at CareDx. “These abstracts and presentations highlight CareDx’s position as a leading provider of genomics-based information in transplantation, with the goal to improve long-term patient outcomes. We collaborate with the many distinguished clinicians in transplantation, and look forward to having them share their latest insights with the broader community at EFI.”
About CareDx CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum, and is the leading provider of genomics-based information for transplant patients.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements, including statements regarding the Company’s participation at EFI. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including general economic and market factors, among others discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed by CareDx with the SEC on March 6, 2019 and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
CareDx, Inc.Sasha KingChief Commercial Officer415email@example.com
Investor RelationsDavid ClairIntegrated Corporate Relations, Inc.firstname.lastname@example.org